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 Diabetic Retinopathy (DR) is a microvascular complication associated with 
diabetes mellitus. DR is an eye disease that occurs as a result of chronic hyperglycemia, 
which causes vascular damage, increased vascular permeability, vascular leakage, and 
edema [1]. Diabetes mellitus or just diabetes is a chronic condition caused by relative or 
absolute deficiency of insulin in the body. DR was responsible for blindness in 5% of the 
world population in 2002 with approximately five million people becoming blind [2]. 
During this time period it was also the third leading cause of blindness in working age 
adults in the United States. In the American Indian population in Oklahoma, diabetes has 
attained an epidemic status. As a result, DR had a higher prevalence of visual impairment 
in Oklahoma Native Americans than other ethnic groups [3].  
 When the blood glucose level is elevated in the body, it can lead to a production 
of growth factors. Among the many growth factors present, vascular endothelial growth 
factor (VEGF) has been recognized as the primary mediator of vascular alteration in DR 
[4, 5].  Several clinical studies have shown how increase in VEGF concentrations within 
the eye are linked to DR [6-11] VEGF expression is induced by hypoxia, hyperglycemia, 
oxidative stress, high glucose, tissue ischemia, all occurring in diabetes. Therefore in 
order to reduce the morbidity and mortality associated with DR, it is important to develop 
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therapeutic strategies for controlling the disease. A potential new therapy for DR is the 
development of anti-angiogenesis drugs that would inhibit the angiogenic function of 
VEGF, thereby reducing VEGF levels within the eye.  
 Angiogenesis is a physiological process involving the growth of new capillary 
blood vessels from pre-existing blood vessels. This involves basement membrane 
degradation, cell migration and alignment, lumen formation, loop formation, blood flow 
initiation, and a new basement membrane formation [12]. It is a fundamental step that 
occurs during wound healing, organ formation and embryonic development, and 
pathologically in disorders such as rheumatoid arthritis [13], diabetic retinopathy and 
cancer (tumor growth and metastasis) [14, 15]. In vitro tissue models are used for 
studying angiogenesis because they create an environment suitable for cell growth that 
closely recapitulates what transpires in vivo. An in vitro angiogenesis model could be two 
dimensional (2D) or three dimensional (3D). For the studies carried out in this research, a 
3D in vitro tissue model was utilized because it provided the third dimension that 
captures the physiological complexity unavailable in 2D models. To mimic the in vivo 
environment, in vitro models were used to control biological conditions, as well as 
analyze isolated processes that contribute to angiogenesis [15, 16]. These models have 
also effectively quantified blood vessel formation in 3D. A 3D in vitro angiogenesis 
model involves using cells of endothelial type grown or embedded within an extracellular 
matrix component (ECM) and adding angiogenic agent(s) that would induce cell 
sprouting, proliferation, migration and differentiation. An  example of a 3D angiogenesis 
model  can be  described by Nehls and Drenckhahn [17]. In this model, endothelial cells 
were seeded on gelatin-coated microcarriers and implanted within a fibrin gel or matrigel 
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[18]. The cells were observed to form multicellular capillary-like structures in response to 
basic fibroblast growth factor (bFGF) and VEGF added to the system. Another model 
involves embedding aorta rings in fibrin or collagen gels in the absence of serum and 
protein supplements [19]. 
  Selecting a suitable ECM and angiogenic agent is crucial for the development of 
a 3D tissue model because ECM provides vascular support essential for maintaining the 
organization of vascular endothelial cells into blood vessels [20] and angiogenic agents 
are responsible for stimulating blood vessel growth in the body [16]. Literature has 
shown VEGF as the key regulator in both physiological and pathological angiogenesis. 
This cytokine was selected because of its potent factor to stimulate endothelial cell 
proliferation, differentiation and migration in blood vessel formation [21]. Collagen was 
also selected because it provides a matrix environment suitable for blood vessel 
formation [22, 23] and constitutes the major protein in the ECM [24].  In vitro 
angiogenesis models utilize endothelial cells grown on a 3D extracellular matrix 
environment. These cells are the most suitable because they line the interior surface of 
the blood vessel and their cellular  functions are involved in many angiogenic events 
[15]. Human umbilical vein endothelial cells (HUVECs) were the type used because they 
are readily obtainable and simple to isolate and culture [25]. 
 This research was divided into two studies. The first study was to develop a 3D 
angiogenesis tissue model to study the effect of a novel anti-angiogenesis drug (CLT-
003, a thalidomide analogue). Thalidomide is a potent inhibitor of new blood vessels 
(angiogenesis) [26]. Thalidomide analogues were created to decrease the harmful side 
effects associated with thalidomide. For the first tissue model, HUVECs were grown on 
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type 1 collagen matrix in a 96 well solid plate format using a growth factor cocktail as the 
stimulant. The effect of the drug was studied on HUVEC viability, proliferation, number 
of sprouts and migration. Limitations of the first tissue model to fully measure the effect 
of CLT-003 on angiogenesis led to the development and characterization of a novel 3D 
angiogenesis vascular tissue model. The second study employed a Transwell® membrane 
well to create a model that better represents physiological conditions. The Transwell® 
membrane plate format was used because of its ability to grant independent and easy 
access to both sides of the monolayer, in the upper and lower compartment of the 
membrane, and the simplification in taking measurements. The Transwell® assay is often 
used in in-vitro angiogenesis models to study endothelial cell migration in response to 
growth factors, [16] but literature has shown that there have been challenges during the 
set up and the quantification stage [15]. Some of these challenges involving the 
quantification of the stages of angiogenesis have been overcome in the new model used 
in this research. The 3D tissue model was characterized by varying collagen thickness 
and VEGF concentration added to the system.  These two variables were investigated on 
HUVEC viability, proliferation, migration and number of sprouts. The new model gave 
an improved in vitro assessment of the angiogenic process because it mimicked in vivo 
events such as viability, proliferation, migration and sprouting. The most suitable 
collagen thickness and VEGF concentration that gave the best results in stimulating 
HUVEC viability, proliferation, migration and number of sprouts would be used to study 
the effect of the anti-angiogenesis drug within the model.  
 The next chapter presents a literature review of the diabetic retinopathy disease, 
its association with angiogenesis, VEGF and the different types of tissue models used for 
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studying angiogenesis. The information provided gives a better understanding of the 







2.1 Diabetic Retinopathy  
 Diabetic retinopathy (DR) is characterized by reduced retinal capillary blood 
flow, retinal and vitreous hemorrhage, reduced visual acuity and eventually blindness. It 
is a disease caused by damage to the small blood vessels in the retina, the light sensitive 
layer of tissue lining the back of the eye.  The retina converts light energy falling on it 
into electrical impulses that can be analyzed by the brain. 
 The earliest stage of DR shows mild non-proliferative abnormalities characterized 
by increased vascular permeability. It is also known as background DR and consists of 
microaneurysms only.  Then it progresses to moderate and severe non-proliferative 
diabetic retinopathy (NPDR) characterized by blurred vision, floaters, loss of central or 
peripheral vision, and flashes of lights. Floaters are black peppery spots in the vision.  
The last stage is known as proliferative diabetic retinopathy (PDR).  This stage is 
characterized by neovascularization (as seen in figure 2.1 below), blurred vision, floaters, 
loss of central or peripheral vision, and flashes of light.  The onset is typically more 
sudden and blurring of vision is more severe than NPDR [27]. Neovascularization is the 
growth of new blood vessels. PDR is more common in patients with type 1 diabetes than 
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type 2 diabetes. The newly formed blood vessels are very fragile, and as a result, flame-
shaped intraretinal hemorrhages are commonly found during opthalmoscopic 
examination. One of the mechanism by which diabetic retinopathy causes blindness is by 
retinal and vitreous hemorrhage through pooling of blood in the back of the eye that 
obscures vision [28]. This may occur suddenly and resolve spontaneously, but if not 
treated timely, it may lead to permanent loss of eyesight. 
 
Figure 2.1  A diagram showing the progression of diabetic retinopathy [29] 
 
  An example of normal vision and vision with progressive diabetic retinopathy is 
shown in figure 2.2 below. As the disease progresses a condition known as Diabetic 
Macular Edema (DME) occurs. DME can be defined as the collection of intraretinal fluid 
in the macular area of the retina, which manifest as slow degradation in and blurring of 




        
Figure 2.2 A scene viewed by a person with normal vision and diabetic 
retinopathy[31] 
 According to the World Health Organization (WHO), DR is one of the leading 
causes of blindness in the world.  In 2002, DR was shown as the fifth leading cause of 
blindness worldwide and accounts for 4.8% of the world population. In the United States, 
it is the third leading cause and accounts for 17%, with age-related macular degeneration 
(AMD) and glaucoma in first and second place, respectively [2]. The development and 
progression of retinopathy in an individual is dependent upon the duration of diabetes. 
Almost all patients with type 1 diabetes and over 60% of patients with type 2 diabetes 
will develop some degree of retinopathy after the first 20 years of having the disease [32]. 
Forty-percent of adults with diabetes age 40 years and above have retinopathy and this 
condition is vision-threatening in 20 % of these patients [33]. Vision-threatening DR can 
be classified in patients having one or more of these: severe NPDR, PDR, and DME. 
People with diabetes that are 50 years and above have two times the risk of vision 
impairment as people in the same age group without diabetes [34].  
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 The present treatments available for DR: laser photocoagulation and vitrectomy 
do not restore lost vision. They are only effective at slowing the progression of 
retinopathy and reducing the risk of severe vision loss. It is therefore important to 
identify and treat patients early in the disease [27]. However, the techniques involved in 
these treatments are invasive and are very likely to have side effects. Though new 
techniques are currently developed, a non-invasive and effective drug treatment that 
would prevent progression of diabetic retinopathy has not yet been discovered.  
 Vascular endothelial growth factor (VEGF) plays a fundamental role in the 
etiology of DR. It serves as the primary mediator of intraocular neovascularization, [4] 
that is the abnormal or excessive formation of blood vessels in the eye. These blood 
vessel formations are induced by hypoxia brought about by the blockage of retinal 
capillaries at the early stages of DR. Hypoxia occurs when there is an inadequate supply 
of oxygen to tissue and this increases the tissue production of angiogenic factors, 
including VEGF, which promotes vascular permeability [35]. It is therefore necessary to 
understand blood vessel formation (angiogenesis) in the body, and the role VEGF plays 
in the angiogenesis process. 
 
2.2  Angiogenesis Process 
 Angiogenesis is the formation of new blood vessels, but it differs from 
neovascularization in that angiogenesis is mainly characterized by the protrusion and 
outgrowth of capillary buds and sprouts from pre-existing blood vessels. In the human 
body, a balance exists between angiogenic factors, which stimulate angiogenesis and 
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anti-angiogenic factors (inhibitors) which inhibit angiogenesis. The balance becomes 
upset when either the concentration of angiogenic or anti-angiogenic factors outweighs 
one more than the other. The result is pathological angiogenesis, where there is an 
abnormal proliferation of blood vessel formation. This can occur in many diseases in 
addition to DR such as cancer, rheumatoid arthritis, psoriasis and atherosclerosis.  
 The angiogenesis process involves two consecutive stages namely neovessel 
growth and neovessel stabilization. A sequence of events occurs during the first stage. 
These events include dissolution of the basement membrane of the “parent” vessel and its 
surrounding matrix, migration of endothelial cells within the created space toward the 
angiogenic stimuli, proliferation of endothelial cells, lumen formation within the 
endothelial sprout, and formation of loops by anastommoses of sprouts. The second stage 
entails the cessation of endothelial cell proliferation, reconstruction of a basement 
membrane around the neovessel, and recruitment and coverage of the immature vessels 
with pericytes. Both stages are equally significant, because without vessel stabilization, 
the immature capillary will undergo apoptosis at a very fast rate and deteriorate [36].   
Figure 2.3 gives a pictorial explanation on the progression of angiogenesis process, from 




Figure 2.3 Progression of Angiogenesis [37] 
  
2.3 Vascular Endothelial Growth Factor  
 VEGF, also known as vascular permeability factor (VPF), is an angiogenic, 
endothelial cell mitogen that stimulates angiogenesis and vasculogenesis i.e. blood vessel 
formation form a de novo production of endothelial cells [38]. This growth factor is a 
heparin-binding, homodimeric glycoprotein with a molecular mass of 45-kDa [39] and 
comes from the sub-family of platelet derived growth factor. The VEGF family consists 
of seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and 
placental growth factor (PIGF). VEGF-A (typically referred to as VEGF) is the most 
important member because of the key role it plays in regulating angiogenesis and 
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vasculogenesis. VEGF-C and VEGF-D are mediators of lymphangiogenesis, while 
VEGF-E and PIGF also induce angiogenesis [40]. VEGF is produced by many cell types 
namely retinal pigment epithelial cells, pancreatic duct cells, Schwann cells, retinal 
capillary pericytes, endothelial cells, glial cells, Müller cells, and ganglion cells [41-45]. 
The expression of VEGF in these cell types is induced by hypoxia through different 
mechanisms [44].  
 
2.3.1 VEGF Isoforms and Receptors 
 VEGF isoforms are a result of alternative exon splicing of a single gene [46]. 
Exon 1-5 spans the receptor binding domain, while exons 6 and 7 span the heparin-
binding domain. There are four major isoforms of VEGF having 121, 165, 189, and 206 
amino acids: VEGF121, VEGF165, VEGF189, and VEGF206, respectively [46-48]. Other 
isoforms are in existence and represent less frequent splice variants; VEGF145, [49] 
VEGF183, [50] VEGF162 [51] and VEGF165b [52]. These isoforms are characterized based 
on their heparin-binding affinity to the extracellular matrix. Their ability to bind heparin 
has an inverse relationship with diffusivity. VEGF121 is acidic with no heparin-binding 
affinity, but is a highly soluble protein. VEGF165 is basic and binds to heparin, while 
VEGF189 and VEGF206 are more basic than VEGF165 and bind very tightly to heparin [53]. 
VEGF165 is a secreted protein, though it has a significant portion bound to the cell surface 
and extracellular matrix. In contrast VEGF189 and VEGF206 remain sequestered in the 
extracellular matrix [54]. However these isoforms may be released in a soluble form by 
heparin. VEGF interaction with heparin was studied in order to address the biological 
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significance of its longer isoforms, it was demonstrated that a loss of heparin binding, 
whether due to alternative splicing or proteolysis, will result in a reduction of the vascular 
endothelial cell mitogenic activity of VEGF [55]. 
 In order for the angiogenesis process to begin, VEGF will need to bind to its 
receptors called VEGF receptors (VEGFRs). The binding of VEGF to its receptor 
induces endothelial cell proliferation, migration, survival and permeability of endothelial 
cells. These receptors are located on the surface of endothelial cells [56] and also on bone 
marrow derived cells [57]. When a member of the VEGF family binds to its receptor, 
dimerization occurs, and they become activated through a process called 
autophosphorylation. Autophosphorylation is the phosphorylation of a kinase protein 
catalyzed by its own enzymatic activity. VEGFRs are structured into seven 
immunoglobulin-like folds in the extracellular domain, a single transmembrane region, 
and a split tyrosine kinase domain, which is interrupted by a 70-amino-acid kinase insert 
domain [35]. VEGF binds to two receptors namely VEGFR-1/Flt-1 (fms-like tyrosine 
kinase) and VEGFR-2/KDR/Flk-1 (kinase insert domain-containing receptor/fetal liver 
kinase). These receptors along with VEGFR-3/Flt-4 are part of the receptor tyrosine 
kinase (RTK) family. The expression VEGFRs differs in specific endothelial cell layers. 
VEGFR-2 is can be found on almost all endothelial cells, while VEGFR-1 and VEGFR-3 
can be found on endothelial cells in distinct vascular layers [58]. VEGF-B binds to 
VEGFR-1, VEGF-C and VEGF-D binds to VEGFR-2 and VEGFR-3, VEGF-E binds to 





2.3.2 VEGF Inhibitors  
 VEGF inhibitors are anti-angiogenic agents that hinder VEGF binding to its 
receptors that promote angiogenesis.  Many VEGF inhibitors have been approved by the 
United States Food and Drug Administration (FDA) to aid in the treatment of diseases 
associated with angiogenesis. Some of these inhibitors include Bevacizumab (Avastin), 
which has been shown to increase the survival rate of patients with cancer, [59] 
Ranibizumab and Macugen (Pegaptanib), which were also approved by FDA for the 
treatment of age-related macular degeneration [60, 61].  
 Thalidomide has also been identified as a strong inhibitor of VEGF and thus 
angiogenesis. It is a powerful teratogen, immunomodulatory and anti-angiogenic drug 
that inhibits blood vessel formation in adults and animals [62-64]. Komorowski et al [65] 
studied the effect of different concentration of thalidomide on VEGF secretion, 
endothelial cell migration, adhesion and capillary tube formation in vitro. It was observed 
that 1 µM to 10 µM thalidomide concentrations inhibited VEGF secretion, and 
thalidomide concentrations of 0.01 µM and 10 µM reduced the number of capillary tubes 
formed, but did not affect cell proliferation. The inhibitory factor of thalidomide has also 
been studied in vivo by D’Amato et al [26] using the rabbit cornea micropocket model, 
where angiogenesis was induced by basic fibroblast growth factor. Due to the side effects 
associated with using thalidomide, derivatives of the drug called thalidomide analogues 
were designed to decrease harmful side effects, while enhancing the anti-angiogenic 
activity of thalidomide. This derivative has been shown from literature to be more 
powerful than thalidomide. For example, Moreira et al reported that thalidomide 
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analogue (cc-1069) inhibited endothelial cell proliferation more effectively than 
thalidomide [66]. 
 
2.4 Various Model Systems 
 A model is a representation of a system that allows for investigation of the 
properties of the system as well as the prediction of future outcomes. Researchers use 
experimental models to better understand how biological systems function and the 
complications associated with them. These models provide an environment for studying 
human diseases and treatments. The biological model systems can be divided into in vivo 
and in vitro models. In vivo models include the human and animal models, while in vitro 
models include two dimensional and three dimensional cell and tissue culture models. 
Examples of these models are shown in figure 2.7 below. 
 
Figure 2.4 The Different Types of Model Systems [67-69] 
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2.4.1 In Vivo Versus in Vitro Model Systems 
 Human models are the ideal models to use in research studies because they are the 
exact environment where pathological conditions occur. However, the ethical issues 
involve constitute the major disadvantage associated with using these models. In an 
unfortunate history of medical research, experiments were performed illegally on human 
subjects without their knowledge, consent, or informed consent [70] and this led to many 
untimely deaths. As a result, researchers cannot use human models to study anything that 
is harmful to human health. In addition, human models are difficult to control due to the 
complex nature of the human biological system. There is also the issue of variability, 
which makes it difficult to analyze the effect of one variable at a time.   
 Animal models have been used as substitutes for human models because of their 
similarities to human cells, tissue and organ functions. They can be used to develop and 
test drugs that may be too hazardous to do so in humans. Another advantage of using 
animal models over human models is the ease of manipulating and controlling variables 
in order to study their effect on the system.  This gives scientists a better understanding of 
the physiological behavior of the system. The disadvantage of using animal models is that 
some of the factors, such as receptors and signaling factors present in animals, may 
behave differently than those present in humans. As a result, an animal model may give a 
poor prediction of disease and/or treatment mechanisms in humans.  
 Two dimensional cell culture models provide more control of experimental 
variables than animal and human models, are less expensive, and easier to use with room 
for improved reproducibility. They consist of cells grown in cell culture medium in a 
monolayer in a variety of formats, for example T-25 cm² and T-75 cm² tissue culture 
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flasks, Petri- dishes or well plates. A major limitation of the 2D models is that they do not 
provide the third dimension that correctly mimics in vivo surroundings. In 2D 
environment, there are no mechanical and biochemical signals, cell to cell 
communication and tissue-specific architecture [71]. Nonetheless, because of their 
simplicity, they are still the most popular models used for in vitro studies.  
 Three dimensional models are more accessible than animal based models and 
overcome the limitations of 2D cell culture systems. These models capture more of the 
relevant complexity associated with the 3D microenvironment, similar to that found in 
vivo where cells proliferate, migrate and differentiate within an extracellular matrix. 
Three dimensional models have also been shown to replicate in vivo-like responses [72, 
73] thus giving a better description of in vivo environment than their 2D counterpart. 
 
2.4.2 Two Dimensional Versus Three Dimensional Cell Culture Models 
 Three dimensional models are becoming popular and very important because they 
reduce the need for animal experimentation and provide a potential bridge for the gap 
between 2D cell culture models and human studies. In 2D model systems, cells grown on 
planar surfaces do not model the 3D living tissues and organs within the human body. 
Cell functions such as proliferation and differentiation, which involves cell to cell 
interactions and cell to matrix interactions are lost under 2D conditions [71]. For this 
reason, the results obtained from using 2D models are not completely reliable when they 
do not correctly mimic the in vivo environment. For example transforming growth factor-
β (TGF-β) inhibited endothelial proliferation in 2D systems, but appeared to be 
ineffective in a 3D culture system [74]. A 3D culture system can provide a higher surface 
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area, three orders of magnitude higher than 2D cultures. This higher surface area allows 
cells to attach and arrange themselves. In addition, cells are not limited by contact 
inhibition in 3D as in 2D; they can attain a higher density closer to that found in tissues, 
provided that nutrients can be efficiently transported [75]. Research has also shown that 
cells exhibit different behavior when grown in 3D cell culture.  For example, it has been 
shown that a higher cell density in 3D culture can generate more monoclonal antibody at 
high titer [76]. Another example shows fibroblast cells with a difference in morphology 
and migration when suspended in collagen gels; in 2D cell culture, the substrate induced 
an artificial polarity between the lower and upper surfaces of these naturally nonpolar 
cells [77, 78]. A 3D ECM has been recognized for epithelial cells because it provides a 
3D environment that promotes epithelial polarity and differentiation [79]. 
 
2.4.3  In Vitro Models of Angiogenesis  
 The aim of every in vitro model is to recapitulate in vivo conditions. In vitro 
models are useful tools in i) studying the various steps occurring in angiogenesis, such as 
cell migration, cell proliferation, and tube formation, ii) modeling pathological 
conditions, as well as understanding the molecular mechanisms of angiogenesis, iii) 
testing the effectiveness of angiogenic and anti-angiogenic agents, and iv) the 
identification and screening of potential drugs [15, 80, 81]. 
 There are two types of in vitro angiogenesis models namely 2D and 3D models. 
These models are classified according to the way the cells reorganize. In the 2D models, 
cells develop tubular structures on the surface of the substrate, but in 3D models, they 
invade the surrounding matrix consisting of a biogel to form 3D structures. The 3D 
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angiogenesis models simulate in vivo environment better than the 2D models because 
they describe more of the steps involved in the angiogenesis process. Furthermore, the 
effect of a gradient of diffusion of nutrients, oxygen, and stimulating factors on the events 
occurring during angiogenesis can be studied in 3D models. Two dimensional models 
lack this third dimension required for carrying out these studies. 
 In vitro angiogenesis was initially demonstrated by Folkman in 1980 where 
bovine capillary endothelial cells cultured in gelatin formed capillary like tubular 
structures [82]. This has set the pathway for the development of other in vitro 
angiogenesis models, which have been designed to simulate in vivo angiogenesis, but due 
to the complex nature of the in vivo process, in vitro models have not been successful in 
fully representing the stages of angiogenesis as a whole [83]. As described by Rakesh 
Jain and colleagues, an ideal in vitro angiogenesis model should have the following 
characteristics. 1) the release rate, the spatial and temporal concentration distribution of 
angiogenic factors or inhibitors should be known 2) it should quantitatively measure the 
structure of the new vasculature 3) it should also quantitatively measure the function of 
the new vasculature (i.e. endothelial cell migration rate, proliferation rate, canalization 
rate, blood flow rate, and vascular permeability 4) the in vitro responses should be 
confirmed in vivo. 5) newly formed and pre-existing host vessels should be clearly 
differentiated and 6) it should be cost effective, reproducible, quick, convenient and 
reliable [84]. Several in vitro models have been developed that closely resemble 
angiogenesis within an in vivo environment. They include endothelial cells grown either 
on the surface or embedded within an extracellular matrix to form 3D tube-like structures 
in response to angiogenic factors [22, 85-88].  
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 In the human body, cells secrete molecules that interact to form a complex 
network, which constitute the extracellular matrix (ECM). A suitable ECM must be 
selected to provide the right structural environment for cells to assemble into tissues. The 
ECM is responsible for the developmental process of the tissue through interaction with 
the receptors on the cells. It also provides a scaffold for cell support, a surface for cells to 
adhere and migrate into the ECM, and serves as a reservoir where growth factors and 
chemicals required for cell metabolic function can be stored [89-92]. Collagen is the most 
abundant protein present in the ECM, making up 25 % of total protein body content [93]. 
It is mainly found in the skin and bone. A number of angiogenesis models use collagen as 
the ECM because it represents the major environment where angiogenic events occur [94, 
95].  
 Endothelial cells line all the blood vessels in the human body, the entire 
circulatory system and are the main constituents of capillaries. For this reason, many in 
vitro angiogenesis models utilize endothelial cells grown in cell culture. Another reason 
is because their cell functions are associated with many angiogenic events, including 
matrix degradation, proliferation, migration and morphogenesis [16]. In vitro 
angiogenesis models that make use of endothelial cells are advantageous over in vivo 
models in the following ways: 1) they are easier and faster to set up and execute, 2) there 
is better control and manipulation of biological functions, 3) angiogenic and anti-
angiogenic factors are more easily evaluated and 4) overall cost is lower [15]. 
Furthermore, endothelial cell functions can be directly assessed, without the involvement 
of other cells or any metabolic processing [81]. The most widely used endothelial cells 
are human umbilical vein endothelial cells (HUVECs) because of their availability and 
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simplicity in culture. Consequently, they have been used in many assays and have been 
shown to have similar behavior with endothelial cells isolated from vascular beds [25]. 
 Vernon and Sage [96] described a quantitative model termed, “the radial invasion 
of matrix by aggregated cells” (RIMAC), which was used to study endothelial cell 
migration and sprout formation within 3D collagen matrices. In this model bovine aortic 
endothelial cells were embedded within collagen gels supported by rings of nylon mesh. 
The collagen plus support were called assay disks. The disk was immersed in nutrient 
media, which resulted in radial movement of endothelial cells into the collagen within 
two to five days. The RIMAC model was characterized by testing the response of the 
endothelial cells to collagen density and the angiogenic protein bFGF, VEGF and 
transforming growth factor (TGF-β1). Their results show that lower concentrations of 
collagen gels (0.3-0.6 mg/ml) support migration and sprout formation of endothelial cells 
than higher concentrations (2 mg/ml). Their results also show that both bFGF and VEGF 
increase endothelial cell invasion in collagen in a concentration-dependent manner, while 
TGF-β1 inhibits invasion for a wide range of concentrations (0.1-30 ng.ml). 
 Other 3D in vitro models using collagen as ECM was described by Davis et al 
[23, 88] to assess capillary morphogenesis formed by endothelial cell invasion into 3D 
collagen matrices. In the first model, endothelial cells were seeded on the surface of 
collagen gel in a 6 mm culture well insert with a porous membrane. The cells were fixed 
and stained after 72 hrs of culture and it was observed that endothelial cells invaded into 
the collagen below the surface of the monolayer and formed capillary sprouts and 
lumenal structures. The second model was a modification of the first model where the 
collagen gel described above was placed on top of a different collagen gel with and 
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without endothelial cells. The top gel was then seeded with endothelial cells to 
investigate whether invasion was induced by the endothelial cell already undergoing 
morphogenesis in the lower gel. It was observed that after 72 hrs of culture, endothelial 
cells on the top gel invaded and underwent morhpogenic changes while migrating into 
the collagen matrix. It was concluded that endothelial cells during morphogenesis may 
release autocrine factors that control EC invasion. The third model was developed on a 
microscope slide so that the morphogenic process could be visualized by means of phase-
contrast microscopy. Invasion of EC into the collagen gel was observed in the same 
manner as the two earlier models described, in addition to tube formation and 
intracellular vacuoles.  
 There are also 3D in vitro models that use fibrin as the ECM. An example of one 
is that developed by Nehls and Drenckhan [17] where endothelial cells from bovine 
pulmonary arteries were seeded on gelatin-coated cytodex-3 microcarriers embedded in 
fibrinogen and induced to polymerize by adding thrombin. Endothelial cells were 
observed to migrate into the fibrin gel forming 3D capillary-like structures. This model 
was used to test the effect of angiogenic factors VEGF and bFGF on capillary sprouting 
and it was observed that VEGF and bFGF at 100 ng/ml and 30 ng/ml, respectively, 
stimulated endothelial cells proliferation followed by increase in capillary-like 
formations. This model was later modified using matrigel in place of fibrinogen as the 
ECM because of its variability and sensitivity to small changes occurring during the 
polymerization of fibrinogen, and also because of the variation that could be associated 
with the thrombin batch [18]. Matrigel is a scaffold made up of ECM and basement 
membrane proteins derived from the mouse Engelbreth-Holm-Swarm sarcoma and 
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enhanced with collagen IV, laminin and nidogen. The matrigel used in this model was a 
reduced growth factor matrigel, which differs from standard matrigel in that it contains 
reduced levels of cytokines and angiogenic factors and has overcome the problems 
associated with increased stimulation in standard matrigel. Endothelial cells were 
discovered to attach and rapidly form tubules within a short time period (4-12 hrs) when 
seeded on matrigel [97]. However, there was a lack of lumen formation, and non-
endothelial cell, including human fibroblasts and glioblastoma cells, had the same tubules 
structure when grown on matrigel [98]. 
  
2.4.4 In Vivo Models of Angiogenesis 
 In vivo angiogenesis models have been developed to confirm results obtained in 
vitro because they represent the exact environment where angiogenesis occur. There are 
several in vivo angiogenesis models, but the most current and frequently used ones in 
today’s practice are the chick chorioallantoic membrane (CAM) model, the corneal 
angiogenesis model, and the subcutaneous implants [99]. 
 The CAM model can be described as the most widely used in vivo model for 
studying angiogenesis [99, 100]. There are two ways to access the CAM of a chick. The 
first way is by placing the test substance, or the tissue or organ graft, directly on the 
CAM of a developed 7-9 day chick embryo through a window created by cutting an 
opening on the eggshell.  The second way is by transferring the egg content into a Petri 
dish prior to applying the test substance [101]. In this case, there is no eggshell involved 
and is considered as an in vitro method, while the former is considered an in ovo method. 
In ovo means, “occurring in the egg or embryo”. The test substance is prepared either in 
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slow-release polymer pellets, absorbed by gelatin sponges, or is air-dried on plastic discs 
[102]. A pictorial diagram of a chorioallantoic membrane is shown in figure 2.4 below.  
 
 
Figure 2.5 Chick embryo chorioallantoic membrane [103] 
 
 The CAM model has been used to study tumor angiogenesis and to test 
angiogenic and anti-angiogenic factors [104]. Tumor angiogenesis was studied by 
grafting tumor samples to the surface of the CAM. Grafting was carried out on day 8 of 
incubation at 37ºC at constant humidity. This evoked a tumor-induced vasoproliferative 
response after 48 to 72 hours made up of newly formed vessels that assembled towards 
the graft. Evaluation of new blood vessels was done by means of a stereomicroscope in 
vivo [105-107]. For testing pro- and anti-angiogenic factors, inert synthetic polymers are 
soaked with these molecules and placed onto the surface of the CAM. Elvax 40 and 
hydron, first described by Folkman and Langer, are examples of polymers commonly 
used [108]. Polymers in combination with an angiogenic factor elicit a vasoproliferative 
response 72 to 96 hours after placement onto the CAM. An increased vessel density was 
observed around the implant with vessels converging towards the center [109]. On the 
other hand, when polymers were combined with an anti-angiogenic factor, the vessels 
were observed to decrease in density and eventually vanished [110]. 
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 The corneal angiogenesis model is considered to be one of the best in vivo models 
of angiogenesis. Since the cornea is normally avascular, the production of an angiogenic 
reaction is the most convincing illustration of true vascularization [111]. The test tumors 
or tissues are introduced in the cornea of rabbits, mice, or rats through a pocket made in 
the cornea at a safe distance from the limbus, as can be seen in figure 2.5. The test 
substances that would induce angiogenesis in the corneal pocket are introduced in slow-
release materials such as the ethylene vinyl copolymer (ELVAX), Hydron, or a sponge 
material. Due to the avascular nature of the cornea, introducing angiogenic stimulators 
creates an environment for easy quantification of blood vessels, thus any vessels formed 
are new vessels [112]. A slit lamp stereomicroscope is used to evaluate the 
vasoproliferative response. Vessel budding from the limbal plexus is scored as a positive 
response, occurring after 3 to 4 days. Capillaries were observed to reach the implanted 
pellet in 7 to 10 days. Implants that do not produce neovessel growth within 10 days are 
scored as a negative response [113]. The number and growth rate of newly formed blood 
vessels are used to estimate the intensity of angiogenic activity. An angiogenic score is 
calculated using the formula of vessel density times the distance from the limbus [114]. 
Other methods have been reported to improve quantification, such as video data 
acquisition and computerized image analysis [115-117].  
 
Figure 2.6 Location of the cornea and limbus on the eye
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2.4.5 In Vitro Versus in Vivo Models of Angiogenesis 
 In vivo models mimic the normal and pathologic states of angiogenesis. In vivo 
models also provide more information than in vitro models as a result of the complex 
cellular and molecular activities of angiogenic reactions, as long as the biology of the 
assay and the experimental design are pertinent [104]. However, there are several 
disadvantages associated with modeling angiogenesis in vivo. They suffer from batch to 
batch variability, making it difficult to maintain homogeneity between experiments. They 
do not have the advantage of controlling one or more variables in order to study the effect 
of a single variable on the system. This makes quantification of the response from a 
single variable very difficult in this model. In vivo models involve numerous cell types, 
which does not allow identification of the direct effects on endothelial cell functions only 
[16]. In addition, they are time consuming, expensive, and require technical expertise in 
animal handling.  The problems associated with in vivo models, limit the number of tests 
than can be performed at a time. Thus, several in vitro models have been developed for 
carrying out studies that have been difficult to assess in vivo.  
 In vitro angiogenesis models are essential because they create an environment 
where researchers can have control of many variables associated with the angiogenesis 
process. They also permit the analysis of isolated processes involved in angiogenesis, 
unlike their in vivo counterparts that model angiogenesis as a whole. In vitro angiogenesis 
models provide an alternative to using animals for testing. They are also less expensive 
than in vivo models, especially when it comes to performing experiments on a large scale 
[16].  They are easily quantifiable, but interpretation of results obtained should be done 
with caution. In vitro models provide initial information and are subject to validation by 
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using in vivo models, since they represent the exact angiogenesis environment. Also more 
than one in vivo model should be used to confirm in vitro results, due to variations that 
exist in species or animals used for testing, microenvironments, organ sites, and method 
of applying the test substances [122]. 
 
2.5 Design of a Novel Three Dimensional Vascular Tissue Model 
 The lack of suitable 3D angiogenesis tissue models that closely mimic 
physiological conditions useful for studying anti-angiogenic drugs led to the development 
of a novel 3D tissue model. The novel design consists of endothelial cells cultured on 
bovine type 1 collagen in a Transwell® permeable support. These supports/inserts are 
positioned in a 24-well tissue culture plate. They have been used to develop 3D models 
that would determine migratory or invasive response of endothelial cells to an 
angiogenesis stimulating or inhibiting factor [123]. Endothelial cells respond to 
angiogenic factors along a gradient through a process called chemotaxis. Chemotaxis as  
seen in figure 2.7 below is defined as cell movement towards an extracellular gradient of 
a bioactive molecules, such as a chemokine or ligand [124].  
 




 The Transwell® insert divides the system into two compartments. A porous filter 
located at the bottom, as can be seen in figure 2.8 below, separates the upper 
compartment from the lower compartment. The membrane pores are of defined diameter 
with 3.0 µm selected for the use of endothelial cells. This pore size allows cell migration 
and diffusion of chemoattractants through the filters to the extracellular matrix, but 
prevents endothelial cells from migrating through the membrane. The use of a porous 
filter in a Transwell® assay was first identified by Stephen Boyden, who studied the 
chemotactic activity of ploymophonuclear leucocytes [126]. The cells were placed in the 
upper compartment, while the chemoattractant was placed in the lower compartment to 
induce migration of leukocytes. This Transwell® assay is known as the Boyden chamber 
or modified Boyden chamber assay and is the most popular assay used for studying cell 
migration. The main advantage of using this Transwell® is because of the sensitivity to 
small changes in concentration gradients [127]. 
  The novel 3D system mimics an environment close to physiological conditions. 
As shown in figure 2.9, blood vessels within the eye are located at the back of the eye. 
When external agents (drugs) for treating diabetic retinopathy are added from the front 
they diffuse through the extracellular matrix towards the blood vessels to hinder 
proliferation and differentiation of endothelial cells.  The novel 3D in vitro design 
provides ports at the sides for easy delivery of the anti-angiogenic drug to the bottom 
compartment. The drug then diffuses through the matrix towards the endothelial cells. 
Thus, this simulates the in vivo environment within the eye and can be used for studying 











1. Develop a 3D vascular tissue model to study angiogenesis 
2. Study the effect of an anti-angiogenesis drug on endothelial cells in the model 
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4. Determine the effect of vascular endothelial growth factor concentration added to the 3D 
vascular tissue model on angiogenesis 








3.1  Materials 
 Human umbilical vein endothelial cells (HUVECs) were purchased from 
PromCell (Heidelberg, Germany); bovine type 1 collagen was purchased from Advanced 
BioMatrix (Tucson, Az); fetal bovine serum (FBS) was purchased from Hyclone (Logan, 
UT); 1X and 10X medium 199, penicillin-streptomycin-glutamine (PSG), trypsin-EDTA 
and dulbecco’s phosphate buffered solution (DPBS) were purchased from Invitrogen 
Corporation (Carlsbad, CA); human fibronectin was purchased from Biomedical 
Technologies Inc. (Stoughton,MA); Cell Titer Blue cell viability assay was purchased 
from Promega Corporation (Madison, WI); vascular endothelial growth factor was 
purchased from R&D Systems (Minneapolis, MN); 24-well transwell® permeable 
supports were purchased Corning Incorporated Life Sciences (Lowell, MA); human 
VEGF ELISA development kit was purchased from Preprotech (Rocky Hill, NJ); Tween 
20 and albumin bovine serum (BSA) were purchased from Sigma-Aldrich (St. Louis, 
MO); ELISA microplates were purchased from Greiner Bio-One (Monroe, NC).
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3.2  Cell Culture 
 HUVECs were cultured in 1X Medium 199 supplemented with 1% PSG and 20% 
FBS. The cells were grown in a T-75 flask in a humidified 5% carbon dioxide (CO2), 
95% air incubator at 37ºC (standard conditions). These conditions were used for all 
experiments. The cell culture media was changed every other day until HUVECs were 95 
-100% confluent. The time period for HUVECs to become confluent was approximately 
seven days.  
 
3.3  Development of a Three Dimensional Vascular Tissue Model to Test the 
Effect of an Anti-Angiogenesis Drug 
 The 3D vascular tissue model consisted of HUVECs grown on a 3D collagen matrix 
within a 96 well solid plate.  The collagen gel was prepared by mixing 8 parts bovine 
type 1 collagen (3 mg/ml), 1 part 10x Medium 199 and 5 parts 0.1 M sodium hydroxide 
in a centrifuge tube. To a single well, 50 µl of the prepared collagen solution was added 
and incubated for an hour for the solution to gel. To the top of each collagen gel, 100 µl 
of complete media containing 20% FBS and 1% PSG was added and incubated at 
standard conditions from 4-24 hrs for the system to attain equilibrium.  The HUVECs 
were seeded on the collagen gel at a density of 100,000 cells/cm² and incubated at 
standard conditions. The complete media was changed the next day and then every other 
day until the cells were 95 % to 100 % confluent. The cells became confluent on collagen 
gels in about five to seven days. Experiments were carried out in triplicate samples. 
Figure 3.1 shows a diagram describing the development of the 3D tissue model.  
 
Figure 3.1 3D vascular tissue model 
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3.3.1 Cell Titer-Blue Viability Assay 
 This assay was used to measure viability and proliferation of HUVECs at 
different time points. The Cell Titer Blue viability assay estimates the number of viable 
cells present in each well by using an indicator dye resazurin, present in a buffered 
solution, to measure the metabolic capacity of cells. The viable cells reduce resazurin into 
resorufin, which is highly fluorescent, but the non-viable cells do not reduce the dye and 
thus give off no fluorescent signal. The reagent is added directly to each well. It is 
initially dark blue in color and has minimum fluorescence until it changes to a pink color. 
This indicates that resazurin has been reduced to resorufin, which is highly fluorescence, 
giving it a pink color. The signal could be measured by either fluorescence or absorbance. 
Fluorescence is the preferred method used as a result of its higher sensitivity and the 
fewer calculations involved. Figure 3.2 shows an overview of the cell titer blue viability 
assay from the first steps of adding the reagent to the final step of measuring the 
fluorescence signal of each sample. 
 
Figure 3.2 Cell Titer-Blue Cell Viability Assay  [129] 
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 In the 3D tissue model, 20 µl of reagent was added (at specified time points) 
directly to the cells in the culture media and incubated for four hours, after which the 
fluorescence signal was measured using a fluorometer. The fluorescence was measured at 
excitation 560 nm and emission 590 nm. The fluorescence signal measured was 
proportional to the number of viable cells. The number of cells were calculated by using a 
quadratic relationship that exists with measured fluorescence, determined by measuring 
standards. Standards were used to relate the number of cells per well to the measured 
fluorescence signal. They were prepared by seeding HUVECs at different seeding 
densities on collagen and incubating them for four hours. The reagent was added to these 
samples, and the fluorescence was measured using the spectrophotometer. A graph of the 
fluorescence signal for the number of cells per well was plotted and the number of cells 
per well was calculated from the quadratic equation shown in figure 3.3 below. 
 
 
Figure 3.3 Fluorescence measured for a known number of cells after the Cell 
Titer Blue assay. 































GF & NGF Poly. (GF & NGF )
36 
 
3.3.2 Microscopic Evaluation of Migration and Number of Sprouts 
 A sprout is a branch or a shoot from a growing cell. Number of sprouts were 
measured by visually counting by using a phase contrast inverted microscope and a cell 
counter. Sprouts were counted for each well at 100x magnification. Since samples were 
done in triplicates, the average and the standard deviations were calculated for number of 
sprouts counted in each well.  Below is a picture showing an example of sprouts at 100x, 
250x and 400x magnifications, respectively. 
 
 
Figure 3.4 Sprouts in the 3D vascular tissue model at 100x, 250x and 400x 
magnification 
 
 Cell migration was measured by calculating the depth of migration from the 
surface of the collagen into the matrix as shown in figure 3.5. A glass cover slip with a 
known thickness was used as a standard to calculate the actual cell migration distance. 
The thickness of the glass cover slip was measured to be 1 mm using a micrometer screw 
gauge. This thickness corresponds to 3.45 revolutions, using the fine-focus knob of the 
microscope. By using the standard measurements, the depth of cell migration was 
determined and the average and standard deviation calculated from triplicate samples. 
 
Figure 3.5 Measuring the d
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in the media.  Thereafter the growth factor media was changed to fresh growth factor 
media without drug on all samples on Days 1, 3, and 7 after adding the drug. On day 9, 
CLT-003 was added again to the test group at twice the initial concentration level, final 
concentration of 64 µM in the media, and the growth factor media was changed on day 
10 and 16. The control group was replaced with fresh growth factor media for the same 
time points. Separate samples were prepared for the viability and proliferation tests and 
for the migration and number of sprouts tests. Viability and proliferation tests were 
carried out on Days 1, 3, 7, 10 and 16. Number of sprouts and migration measurements 
were carried out on Days 2, 3, 6, 9, 10, 13, and 16. Analyses were performed before the 
fresh growth factor media and drug media were added to the samples. At the required 
time point, the viability and proliferation, and migration and number of sprouts were 
analyzed as described in sections 3.3.1 and 3.3.2 using the cell titer blue viability assay 
and microscopic evaluation, respectively. 
 
3.3.4 Effect of Thalidomide Analogue on Endothelial Cell Viability, Proliferation, 
Number of sprouts and Migration in Normal Model. 
 The second model was called the Normal Model due to the absence of a growth 
factor cocktail. It was made up of cells cultured in M199 with 20% FBS and 1% PSG. 
The effect of the two drug concentrations, 32 µM and 64 µM was also tested on cell 
viability, proliferation, migration and number of sprouts within this model. However, the 
two drug concentrations were tested separately and only applied to the samples once. As 
before, the control group for this experiment was samples with media containing no drug. 
When cells were 95% to 100% confluent, within 24 hours the media were removed from 
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the samples and fresh media containing either 32 µM or 64 µM of CLT-003 for the test 
samples or no drug for the control samples were added.  This day was called day 0. The 
media was changed on all samples to fresh media on days 1, 4, 7, 10, and 13. Separate 
samples were prepared for cell viability and proliferation samples and for number of 
sprouts samples. These tests were carried out as described in section 3.3.1 and 3.3.2 on 
days 1, 3, 7, 10 and 14 days after adding CLT-003.  
 
3.4  Characterization of Novel 3D Angiogenesis Tissue Model  
 A novel 3D angiogenesis model that better mimics physiological conditions than 
the previous models was developed. It consists of HUVECs grown on collagen gels in 
Transwell® permeable supports/inserts. These inserts are placed in each well of a 24 well 
plate. Each insert has a microporous membrane located at the bottom of the insert. The 
membrane is 6.5 mm in diameter, has a pore size of 3.0 µm, and an insert membrane 
growth area of 0.33 cm². The Transwell® supports are made from polycarbonate and 
have a nominal membrane thickness of 10 µm and 2 x 10
6
 pores/cm² nominal pore 
density. The Transwell® inserts divide the model into two compartments, referred to as 
the upper and the lower compartments. This format provides access to the top and bottom 
surface of the collagen matrix for easy delivery of factors, which makes it more 
advantageous than previous models where factors could only be delivered to the top 
surface of the matrix. Figure 3.6 shows the Transwell® membrane wells and the process 
for making the 3D vascular tissue model. Collagen solution (8 parts bovine type 1 
collagen (3 mg/ml), 1 part 10x Medium 199 and 5 parts 0.1 M sodium hydroxide) is 
added to the inserts at 50 µl volume and incubated for one hour at standard conditions to 
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3.4.1  Effect of Vascular Endothelial Growth Factor and Collagen Thickness on 
Endothelial Cell Viability, Proliferation, Number of Sprouts and Migration 
 Changes in VEGF concentration and collagen thickness were the two design 
variables chosen to characterize the new 3D tissue model.  VEGF concentration was 
varied at 5 ng/ml, 50 ng/ml and 100 ng/ml, and collagen thickness was varied at 0.73 
mm, 2.01 mm and 4.28 mm. The effect of VEGF concentration added to the model and 
changes in collagen thickness on endothelial cell viability, proliferation, number of 
sprouts and migration was studied.  
 To test the two design variables, for a single experiment, collagen thickness was 
held constant and VEGF concentration was varied.  A control group containing no 
addition of VEGF was used to normalize the samples, in order to compare them to other 
experiments with a different collagen thickness.  In more detail, the 3D vascular tissue 
model was constructed by setting the collagen thickness.  Collagen thickness was set by 
controlling the volume of collagen solution added to each well.  For the first experiment, 
50 µl of collagen solution was added to each well, which resulted in a collagen gel 
thickness of 0.73 µm.  To the top compartment, 100 µl of complete media was added and 
to the bottom compartment 650 µl of complete media containing either 0, 5, 50, or 100 
ng/ml of VEGF was added to their respective wells. VEGF was added to the bottom 
chamber in order to simulate physiological conditions.  In vivo, VEGF is released by 
cells into the surrounding ECM, which leads to concentration gradients that can stimulate 
cell proliferation and directional cell sprouting and migration.   Delivery of VEGF to the 
bottom chamber can lead to concentration gradients within the collagen matrix that would 
stimulate cell proliferation, migration, and sprouting from the HUVES on the top surface.  
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The plates were incubated and the media was changed with fresh complete media in the 
top compartment and fresh VEGF growth factor media in the bottom compartment of the 
plates in their respective wells on Days 3, 6, 9, 12, and 15 post seeding. Prior to media 
changes on these days, viability and proliferation, number of sprouts, and migration 
analyses were performed. Viability and proliferation analysis was performed on one set 
of tissue model samples and migration and number of sprouts analyses were performed 
on another set of tissue model samples, all following the same experimental conditions. 
The experiment was repeated for the next two collagen thicknesses of 100 µl and 150 µl 
collagen solution added to each well, which resulted in 2.01 mm and 4.28 mm collagen 
gel thicknesses, respectively. 
 For this model, viability and proliferation was also measured using the cell titer-
blue viability assay. Due to the porous membrane at the bottom of the insert, the protocol 
had to be modified. If the reagent was added to the top of the wells, it would leak through 
the pores and be diluted in the solution in the bottom compartment. In order to prevent 
the reagent from leaving the top compartment, parafilm was gently wrapped round the 
lower portion of the insert and a rubber ring was attached onto this lower portion as 
shown in figure 3.7 below. The parafilm and the rubber stop were able to hold the reagent 





Figure 3.7 Front and bottom view of the membrane insert 
 
At each time point, the culture medium in the top and bottom compartments was 
aspirated for the wells to be analyzed. Next, the parafilm and rubber ring were attached to 
the insert as described above. Then 100 µl of fresh complete media was added to the top 
of the collagen followed by 20 µl of cell titer blue reagent. The plates were placed inside 
the incubator for four hours. At the end of the incubation period, the reagent in the 
complete media on top of the gel was mixed gently using a micro pipette and 100 µl of 
sample was transferred from each well into assigned wells in a 96 well plate. The 
fluorescence signal for each well was measured using the spectrophotometer. Cell 
migration and number of sprouts were analyzed as described in sections 3.3.2.  
 
3.5 Statistical Analysis 
Data is expressed as mean ± standard deviation for n = 3 samples.  Data was 
analyzed by use of a student’s t-test to determine the significance of any difference 
between the groups tested and the control.  A value of p < 0.05 was considered 
significant.  Sample measurements were normalized based on the 0 ng/ml VEGF 





RESULTS AND DISCUSSION  
 
4.1 Development of a Three Dimensional Vascular Tissue Model to Test the 
Effect of an Anti-Angiogenesis Drug 
 4.1.1 Effect of thalidomide analogue on viability, proliferation, number of 
sprouts and migration in the Growth Factor Model 
      The aim of this study was to develop a three dimensional vascular tissue model, 
which can be used to study the effect of a novel anti-angiogenesis drug called CLT-003, a 
thalidomide analogue, on angiogenesis. The 3D in vitro model was made up of HUVECs 
grown on a bovine type 1 collagen matrix in a 96 well solid plate using a growth factor 
cocktail as the stimulant. HUVECs viability, proliferation, number of sprouts and 
migration was measured within the vascular tissue model in order to determine the effect 
of CLT-003 on angiogenesis. Collagen was the extracellular matrix (ECM) selected 
because it is the most abundant protein in the ECM. Out of the 25 different collagen 
molecules present, type 1 is the most widely distributed in the body; it accounts for 90% 
of the collagen in the human body. In addition, it provides the chemical and physical cues 
required to stimulate morphogenesis and many cell functions [130]. Angiogenic growth 
factors are essential for promoting the angiogenic events that occur during the 
angiogenesis process. For this model, the growth factor cocktail based on Davis and 
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Camarillo’s [131] work was chosen to stimulate proliferation and differentiation of 
endothelial cells. The growth factor cocktail consists of 40 ng/ml VEGF, 40 ng/ml bFGF, 
50 ng/ml phorbol ester, and 50 µg/ml ascorbic acid.  
Due to the use of a growth factor cocktail, this model is referred to as the Growth 
Factor model. In this model, the effect of CLT-003 at two concentrations, 32 µM and 64 
µM, on endothelial cell viability, proliferation, number of sprouts and migration was 
tested.  When endothelial cells were 100% confluent, the drug was added at 32 µM and 
the time considered as Day 0. Cell viability and proliferation was measured using the Cell 
Titer Blue viability assay on Days 1, 3, and 7. It was observed that at the 32 µM 
concentration of CLT-003, there was no significant change in the angiogenesis 
mechanisms, thus the drug dosage was doubled and 64 µM was added on Day 9. 
Viability and proliferation was measured on Days 10 and 16. During the experimental 
period, the media containing the growth factor cocktail was changed on the same day 
when viability and proliferation measurements were carried out, on Days 1, 3, 7, 10, and 
16. Figure 4.1 shows the effect of the drug on cell viability and proliferation for the 
various time points. Samples without the addition of CLT-003 served as the control 
group.  
When CLT-003 was added at 32 µM on Day 0, there was a slight decrease in the 
number of cells per well from Days 1 to 3 of approximately 125,000 cells per well on 
Day 1 to 115,000 cells per well on Day 3. The control samples on these two days were 
observed to increase from approximately 154,000 cells per well on Day 1 to 164,000 cells 
per well on Day 3. This was an indication of the early effects of the drug in reducing cell 
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viability.  The decrease in the number of viable cells per well was significant for the 
CLT-003 group compared to the control group, but the decrease in the number of viable 
cells per well for the CLT-003 from Day 1 to Day 3 was not significant.   
 
 
Figure 4.1 Effect of CLT-003 on cell viability and proliferation in the Growth Factor 
Model. Data shown are mean values ± sd; n=3. The samples with CLT-003 showed a 
significant decrease in the average number of viable cells per well compared to the 













































From Day 3 to 7, it can be seen that the number of viable cells increased significantly 
from approximately 115,000 cells per well to 154,000 cells per well. However, the 
increase was not as great as compared to the control, which also had an increase of 
approximately 164,000 cells per well to 197,000 cells per well. This increase does not 
reflect the normal mechanism of the thalidomide analogues in hindering viability and 
proliferation of endothelial cells in vitro [66]. Therefore, it was concluded that the 32 µM 
CLT-003 concentration reduced endothelial cell viability and proliferation initially, but 
the cells started to recover and cell viability and proliferation increased. When the drug 
concentration added to the tissue model was increased to 64 µM, cell viability and 
proliferation was significantly reduced, compared to the samples with only 32 µM of the 
drug and the control. There was a significant decrease from approximately 154,000 cells 
per well on Day 7 to 10,000 cells per well on Day 16. These results signify that a higher 
thalidomide concentration produces a greater effect in reducing endothelial cell viability 
and proliferation. The observed decrease on Day 16 may not be completely attributed to 
the increase in drug concentration, since the viability of the control samples decreased as 
well. A significant decrease in number of viable cells per well was also observed for the 
control samples on Day 10 and Day 16 from approximately 180,000 cells to 97,000 cells 
per well respectively. This may show that the cells are only viable in this type of culture 
system and conditions for 16 days. Therefore, the effects of the drug should be tested 
when the cells are fully viable, within the 16 day limit. It was concluded that CLT-003 at 




The effect of CLT-003 on endothelial cell sprouting and migration was also 
studied within the collagen matrix in the model. Figures 4.2 and 4.3 show the average 
number of sprouts and depth of cell migration with time for samples with and without the 
drug added. Samples without CLT-003 served as the control. Both the number of sprouts 
and cell migration were measured microscopically. Cell migration was measured as the 
distance the cells migrated from the surface of the collagen down into the collagen 
matrix.  The drug was added to the samples at 32 µM on Day 0 and 64 µM was added on 
Day 9.  Cell sprouting and migration measurements were carried out on Days 2, 3, 6, 9, 
10, 13, and 16. As shown in figure 4.2, the number of sprouts was observed to increase 
with time for the control samples. There was an increase of approximately 80, 120, 180, 
300, 360, 410, and 600 sprouts per well on Days 2, 3, 6, 9, 10, 13, and 16 respectively. 
After the addition of 32 µM of CLT-003, no sprouts were observed on the Days 2 and 3 
compared to the control sample. However, sprouts were observed on Days 6 and 9 with 
29 and 53 sprouts, respectively. Adding CLT-003 at 64 µM on Day 9 removed existing 
sprouts and prevented cell sprouting for five days. Possible sprout recovery was observed 
on Day 16 with approximately two sprouts (not visible in the figure). Figure 4.3 shows a 
similar effect for the depth of cell migration. The control group samples showed 
enhanced migration of 0.37 mm, 0.35 mm, 0.61 mm, 0.62 mm, 0.60 mm, 0.68 mm, and 
0.69 mm on Days 2, 3, 6, 9, 10, 13 and 16, respectively. No migration was observed after 
adding 32 µM CLT-003, until Days 6 and 9 with 0.35 mm and 0.40 mm migration depth, 
respectively. There was also significant cell migration of 0.29 mm on Day 16 after adding 





Figure 4.2 Effect of CLT-003 on the number of sprouts in the Growth Factor Model. 
Data shown are mean values ± sd; n=3. The samples with CLT-003 showed a 
significant decrease in the number of sprouts per well compared to the samples 








































Figure 4.3 Effect of CLT-003 on cell migration in the Growth Factor Model. Data 
shown are mean values ± sd; n=3. The samples with CLT-003 showed a significant 
decrease in cell migration compared to the samples without CLT-003 (p<0.05). 
 
The recovery observed for both cell sprouting and migration is believed to be the result of 
adding the growth factor media, which counteracted the normal mechanisms of the drug. 
It can also be observed that both cell sprouting and migration recovery occurred six days 
after adding the drug at the lower concentration and seven days after adding the drug at 
the higher drug concentration. This recovery shows that for this model, CLT-003 may no 



















































is possible that cell recovery in sprouts and migration may be described as a phenomenon 
known as ‘secondary sprouting’ where endothelial cells were observed to survive after 
tube collapse and migration from secondary sprouts occurs [132]. Comparing these 
results to those for viability and proliferation, it was observed that CLT-003 had a more 
significant effect on the number of sprouts and cell migration than viability and 
proliferation, compared to the respective control samples.  
Based on the results, it was concluded that the growth factor model was not 
suitable for studying the effect of CLT-003 on angiogenesis within the tissue model 
because the growth factor cocktail induced endothelial cell recovery after adding either 
32 µM or 64 µM of CLT-003. Since it is believed that the growth factor cocktail 
competes with the drug, another model was developed by taking the growth factor 
cocktail out of the system. This model was called the Normal Model. 
 
4.1.2 Effect of thalidomide analogue on viability, proliferation and number 
of sprouts in the Normal Model 
      For the Normal Model, CLT-003 concentrations of 32 µM and 64 µM were 
added to separate samples on Day 0, in order to test the effect of the drug at various 
concentrations on angiogenesis within the model. Samples were analyzed on Days 1, 3, 7, 
10 and 14 after adding the drug. The complete media was changed on Days 1, 4, 7, 10 
and 13 after adding the drug. For sample analysis and media changes occurring on the 
same days, samples were taken for analysis prior to media changes. Samples without 
CLT-003 added served as the control. Figures 4.4 and 4.5 shows the effect of CLT-003 
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on endothelial cell viability and the number of sprouts for the two drug concentrations 
added to the Normal Model, respectively. 
As shown in Figure 4.4, compared to the control, a significant decrease in 
viability was observed when 32 µM and 64 µM CLT-003 were added to the cells. The 
addition of the higher thalidomide concentration to the samples showed a more 
significant decrease in cell viability with time compared to the control than for the 
addition of the lower drug concentration.  When comparing cell viability in the Normal 
Model compared to the Growth Factor Model, no cell recovery was observed, and the 
drug demonstrated its expected mechanism in reducing cell viability and proliferation.  
Comparing Day 1 of the two models after adding 32 µM CLT-003, the Normal Model 
had a more significant decrease in cell viability than the Growth Factor Model with a 
decrease of approximately 32% compared to 19%, respectively. The viability of the 
control samples in Figure 4.4 were observed to increase significantly from Day 1 to Day 
10 with approximately 76,000 cells per well and 115,000 cells per well, respectively. 
However, a decrease was observed from Day 10 to Day 14 with approximately 115,000 
cells per well and 77,000 cells per well, respectively. A similar effect was also seen in the 
control samples for the Growth Factor Model. This shows that cell viability and 
proliferation may be limited to approximately ten days for the solid well plate format 
either with or without growth factors.  
To further demonstrate the effectiveness of the drug on angiogenesis in the model, 
the number of sprouts was also investigated, and the results are shown in Figure 4.5. 
After the drug was added, no sprouts were observed on the Day 1 and 3. Possible sprout 
recovery was observed from Days 7 to 14 for both CLT-003 concentrations. However, 
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due to the large standard deviation for these samples, the number of sprouts may be 
insignificant.  Any possible recovery may be due to the regular change in complete 
media, which dilutes the drug within the system.  
 
 
Figure 4.4 Effect of thalidomide analogue on viability and proliferation in the 
Normal Model. Data shown are mean values ± sd; n=3. The samples with CLT-003 
showed a significant decrease in cell viability and proliferation compared to the 
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Complete media also naturally contains low levels of angiogenic factors, which stimulate 
cell growth and sprouting. The control samples in Figure 4.5 were observed to also 
increase with time from approximately 15 sprouts on the Day 1 to 53 sprouts on Day 14.  
 
Figure 4.5 Effect of CLT-003 on the number of sprouts in the Normal Model. Data 
shown are mean values ± sd; n=3. The samples with CLT-003 showed a significant 
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Without the presence of a growth factor cocktail, CLT-003 at both concentrations 
significantly reduced viability and proliferation of endothelial cells with time. The 
Normal Model also showed minimal sprout recovery compared to the Growth Factor 
Model. Thus from the overall study with CLT-003, it can be concluded that the Normal 
Model was more suitable for studying the effect of the drug on angiogenesis than the 
Growth Factor Model. Even though it was a better model, there was still a need to 
improve the viability of endothelial cells in the control samples for the model. It was also 
necessary to find an alternative method to deliver the drug to the tissue model that better 
mimics how the drug is administered to the eye. For drug delivery to the eye, the drug is 
delivered to the front of the eye and diffuses through the matrix to reach the blood vessels 
located at the back of the eye. In the solid well plate tissue models, the drug was 
administered directly to the cells, which corresponds to the drug being delivered directly 
to the blood vessels, and thus did not give an accurate description of what happens in 
vivo. A better representation of in vivo conditions would be delivery of the drug to the 
collagen matrix side, so the drug can diffuse through the collagen matrix and reach the 
endothelial cells on the other side. For this reason, a new model that would improve the 
viability of endothelial cells and allow for the delivery of factors to the matrix site was 
developed. It is proposed that this new system would be a better physiological model 
because it gives a better imitation of drug delivery to the eye and angiogenesis occurring 
within the eye than the other models. The two variables tested in the new model were the 
concentration of VEGF added to the cells and the collagen thickness. The improved 
model could then be used to study the effectiveness of CLT-003 and other therapeutic 
strategies on angiogenesis. 
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4.2 Characterization of a Novel 3D Angiogenesis Tissue Model.  
When designing this model, changes in VEGF concentration and collagen 
thickness were tested as the design variables because they have been shown from 
literature and previous work to be important variables affecting the angiogenesis of 
endothelial cells within a 3D model. HUVECs were chosen for this study because of their 
use in previous experiments and other studies in literature. Membrane plates were used to 
develop the 3D model. Each well in the plate contains a permeable membrane 
insert/support that divides the well into two compartments. A microporous membrane 
located at the bottom of the insert separates the two compartments and allows passage of 
factors from the upper compartment to the lower compartment in the well.  The 
membrane plates provide access to a basolateral compartment to deliver a VEGF and 
access to an apical compartment to deliver complete media in the absence of VEGF. 
Delivery of VEGF this way would provide easy delivery of nutrients to the cells and it 
would simulate the diffusion of VEGF through the matrix to reach its receptors located 
on the endothelial cells on the top surface, similar to as it occurs in vivo. The ability to 
deliver VEGF to the endothelial cells in this manner makes the membrane plate format 
more advantageous than the solid plate format.  
VEGF is an endothelial cell-specific mitogen known to induce proliferation and 
differentiation of endothelial cells that occurs in angiogenesis.  Therefore one of the aims 
of this study was to investigate the effect of VEGF on HUVECs viability, proliferation, 
number of sprouts and migration in the novel 3D angiogenesis tissue model. VEGF 
concentration was varied at 5 ng/ml, 50 ng/ml and 100 ng/ml in order to measure the 
effect of different levels of stimuli on endothelial cell angiogenesis within the 3D tissue 
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model. Viability, proliferation, number of sprouts and migration of HUVECs were 
measured on Days 3, 6, 9, 12, and 15 after the addition of VEGF. VEGF was not added to 
Non-Growth Factor (NGF) samples and served as the control group. The control group 
was cultured in media containing 10% FBS and 1% PSG. FBS is an essential requirement 
for cells, it enables cells to proliferate and live properly within an in vitro environment. 
However, it is not as effective as VEGF, which also stimulates sprouting and migration of 
endothelial cells. 
Collagen is an essential structural protein in the ECM that supports endothelial 
cell growth and provides a medium for cell movement and interactions. The the second 
aim was to study the effect of collagen thickness on HUVECs viability, proliferation, 
number of sprouts and migration in the novel 3D angiogenesis tissue model. The collagen 
thickness in the tissue model mimics the distance between an endothelial cell and the 
source of stimulant, i.e. VEGF. The thickness also represents the diffusional distances a 
factor must travel to reach the cells, which results in local concentration gradients. 
Collagen thickness was varied at 0.73 mm, 2.01 mm, and 4.28 mm.  
 
4.2.1 Effect of vascular endothelial growth factor on endothelial cell viability and 
proliferation 
Figure 4.6 describes the percent difference in viability and proliferation of 
endothelial cells with time in response to increasing VEGF concentrations for the tissue 
model with a collagen thickness of 0.73 mm compared to the NGF control group. The 
percentage values above zero represents more viable cells compared to the NGF sample 
and percentage values below zero represent less viable cells compared to the NGF 
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sample.  It can be observed that when 5 ng/ml VEGF was added to cells, it slightly 
increased viability and proliferation; however, these values were not significant 
compared to the control.  
 
Figure 4.6 Effect of VEGF concentration on viability and proliferation in the tissue 
model with 0.73 mm collagen thickness. Data shown are mean values ± sd; n=3. 
*p<0.05  vs. Non-Growth Factor sample. 
When 50 ng/ml VEGF was added, a significant increase in viability was observed on 
Days 3, 9, 12, and 15 with 65%, 45%, 42%, and 88%, respectively. A significant increase 
was also observed when cells were exposed to 100 ng/ml VEGF concentration on Days 3, 
















































50 ng/ml and 100 ng/ml VEGF concentrations had a greater effect in stimulating cell 
viability and proliferation than 5 ng/ml compared to the control. However, it was also 
observed that 100 ng/ml did not significantly increase viability and proliferation 
compared to the 50 ng/ml. The results obtained for 0.73 mm collagen thickness suggests 
that VEGF stimulates viability and proliferation of endothelial cells with an increase in 
VEGF concentration. 
 Figure 4.7 describes the percent difference in viability and proliferation of 
endothelial cells when exposed to various concentrations of VEGF for the tissue model 
with 2.01 mm collagen thickness compared to the NGF control group. When the collagen 
thickness is 2.01 mm, 5 ng/ml VEGF slightly increased cell viability and proliferation; 
however this effect was not significant compared to the control. When 50 ng/ml of VEGF 
was added to the cells, this gave a significant increase of approximately 73%, 31%, 
216%, 170% and 146% on Days 3, 6, 9, 12 and 15, respectively. Adding 100 ng/ml 
VEGF to the cells also resulted in a significant increase of approximately 76%, 187%, 
194% and 156% on Days 3, 9, 12 and 15, respectively. This increase in cell viability and 
proliferation clearly suggests that 50 ng/ml and 100 ng/ml has the same effect on viability 
and proliferation in this collagen thickness as shown in the 0.73 mm collagen thickness 
samples. Also, both concentrations show approximately the same effect on endothelial 
cells for both collagen thicknesses tested. The reason the 100 ng/ml concentration does 
not show an increase in cell viability and proliferation compared to the 50 ng/ml 
concentration may be due to cell receptor saturation.  For example, there is a maximum 
number of receptors on the cell surface to bind with VEGF and the 50 ng/ml VEGF 
concentration leads to enough VEGF in the system to bind with all of these receptors. 
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Therefore, the 100 ng/ml concentration leads to excess VEGF in the system that cannot 
bind with the receptors and does not lead to any further stimulation of the cells.     
 
 
Figure 4.7 Effect of VEGF concentration on viability and proliferation in the tissue 
model with 2.01 mm collagen thickness. Data shown are mean values ± sd; n=3. 
*p<0.05  vs. Non-Growth Factor sample. 
  
 Figure 4.8 illustrates the percent difference in viability and proliferation of 
endothelial cells in response to increasing VEGF concentration for the tissue model with 

















































shows no significant increase in cell viability and proliferation for this collagen thickness, 
when compared to the NGF control group. Endothelial cell viability was observed to be 
less than 25% in this collagen thickness for each VEGF concentration, which is 
significantly lower when compared to the 2.01 mm and 0.73 mm collagen thicknesses 
with cell viability and proliferation of approximately 200% and 100%, respectively. The 
decrease in viability and proliferation could possibly be due to insufficient nutrients 
and/or oxygen supplied to the cells, leading to a relative decrease in viability and 
proliferation within the 4.28 mm collagen thickness. Thus, the results suggest that 
increasing VEGF concentration has a negligible effect on viability and proliferation in 
4.28 mm collagen thickness.  
 
Figure 4.8 Effect of VEGF concentration on viability and proliferation in the tissue 
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4.2.2 Effect of vascular endothelial growth factor on endothelial cell number of 
sprouts 
  The effect of VEGF concentration on the number of sprouts was also examined as 
shown in Figure 4.9 below. This graph illustrates the total number of sprouts counted per 
well in response to increasing VEGF concentration in the tissue model with 0.73 mm 
collagen thickness compared to the NGF control group (0 ng/ml VEGF). When 5 ng/ml 
of VEGF concentration was added to the cells, a slight increase in sprouts from 
endothelial cells was observed, but was not significant compared to the control. For the 
samples with 50 ng/ml VEGF added, there was a significant increase in sprout formation 
on Days 3 and 6 with approximately 17 and 23 sprouts, respectively. For the samples 
with 100 ng/ml VEGF added, there was a significant increase in sprout formation on 
Days 3, 6, and 12 with approximately 19, 11 and 14 sprouts, respectively. These results 
suggest that the number of sprouts from the cells increased when 50 ng/ml and 100 ng/ml 
VEGF concentrations were added to the cells, compared to the addition of the 5 ng/ml 
VEGF concentration. Each VEGF concentration was observed to increase cell sprouting 
on Day 9, however the samples show large standard deviations, which can be attributed 
to the high variability in analyzing the triplicate samples. A rapid increase in the number 
of sprouts was observed from Day 12 to 15 for the control group. Compared to this 
group,  5 ng/ml VEGF concentration had a - 6% decrease,  50 ng/ml VEGF concentration 
had an 8% increase, and 100 ng/ml VEGF concentration had a 21% increase in the 




Figure 4.9 Effect of VEGF concentration on the number of sprouts in the tissue 
model with 0.73 mm collagen thickness. Data shown are mean values ± sd; n=3. 
*p<0.05  vs. 0 ng/ml VEGF sample. 
 
 On Day 15, viability was observed to be as high as 3% for 5 ng/ml VEGF, 88% for 50 
ng/ml VEGF, and 100 % for 100 ng/ml VEGF, compared to the control. This suggests 
that viability and proliferation is independent of the number of sprouts from the cell 
within the tissue model.  The effect of viability and proliferation on the total number of 
sprouts was also studied within the 2.01 mm and 4.28 mm collagen thicknesses (Data not 
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sprouts observed for the tissue models with these collagen thicknesses.  For this result, 
VEGF increases number of sprouts in only one collagen thickness, the 0.73 mm.  
 
4.2.3 Effect of vascular endothelial growth factor on endothelial cell depth of 
migration 
  Figure 4.10 describes the maximum depth of migration achieved by the 
endothelial cells in response to increasing VEGF concentrations with respect to the NGF 
control group. For cell migration analyses in this model, the distance travelled by the cell 
into the collagen was measured for each triplicate sample and the average was calculated. 
Though cells are within the same culture conditions, there is a possibility that cell 
migration in each sample may vary, which would reflect large standard deviation in the 
data. Compared to the control group, 5 ng/ml of VEGF concentration showed an increase 
in depth of migration on Days 3, 9 and 15 with 0.59 mm, 0.47 mm, and 0.37 mm, 
respectively and a decrease on Days 6 and 12 with 0.44 mm and 0.36 mm, respectively. 
These values suggest that 5 ng/ml VEGF was not potent in enhancing cell migration into 
the collagen. When 50 ng/ml of VEGF was added, there was an increase in cell migration 
of approximately 0.66 mm, 0.65 mm, 0.47 mm and 0.46 mm on Days 3, 6, 9, and 15 
compared to the control, respectively. However, minimum viability was observed on 
Days 9 and 12 for the samples exposed to 50 ng/ml VEGF. When 100 ng/ml VEGF was 
add to the tissue model, there was an increase in cell migration into the collagen with 
approximately 0.61 mm, 0.62 mm, 0.66 mm, 0.54 mm, and 0.48 mm on Days 3, 6, 9, 12 
and 15, respectively. This suggests that 50 ng/ml and 100 ng/ml of VEGF enhanced cell 
migration into the collagen more than compared to 5 ng/ml of VEGF. The effect of 
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VEGF concentration on the depth of cell migration within the tissue model was also 
studied within the 2.01 mm and 4.28 mm collagen thicknesses (Data not shown). 
However, compared to the NGF control, there was no significant cell migration observed 
for these thicknesses. In conclusion, VEGF enhanced cell migration in only the 0.73 mm 
collagen thickness and this was dependent on an increase in VEGF concentration.  
 
 
Figure 4.10 Effect of VEGF concentration on depth of migration in the 0.73 mm 
collagen thickness. Data shown are mean values ± sd; n=3. *p<0.05  vs. 0 ng/ml 






































4.2.4 Effect of collagen thickness on endothelial cell viability and proliferation 
 Figure 4.11, 4.12 and 4.13 illustrates the percent difference in cell viability and 
proliferation associated with increasing collagen thickness for 5 ng/ml, 50 ng/ml and 100 
ng/ml VEGF concentrations compared to the NGF control group, respectively.  It can be 
observed that cell viability and proliferation increased slightly in each collagen thickness 
for 5 ng/ml. However, taking the standard deviation into consideration, this increase was 
not significant compared to the control. This shows that the addition of the low 
concentration of VEGF to the tissue model did not stimulate an increase in cell viability 
and proliferation in any of the collagen thicknesses tested, compared to the NGF control 
sample.  
  According to Figure 4.12 for samples exposed to 50 ng/ml, there was an increase 
in cell viability and proliferation for the 2.01 mm collagen thickness samples on Days 6, 
9, 12, and 15 with 31%, 216%, 170%, and 146% compared to the 0.73 mm collagen 
thickness samples, respectively. On the other hand, the 4.28 mm collagen thickness 
samples showed a significant decrease in cell viability and proliferation compared to the 
0.73 mm collagen thickness samples on Days 3, 9, 12 and 15 with 26%, 2%, 7% and 
11%, respectively. These numbers reassert the multi-functional role collagen plays in 
supporting endothelial cell viability and proliferation. Since collagen can serve as a 
storage site for growth factors, increasing the collagen thickness from 0.73 mm to 2.01 
mm may provide more storage for VEGF and induce greater cell viability and 
proliferation. Therefore, increasing collagen thickness to 4.28 mm should show even 
greater cell viability and proliferation, but this was not the case. The decrease in cell 
viability and proliferation for the 4.28 mm thickness suggests that there may be other 
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factors (such as oxygen) responsible for endothelial cell growth as well. For example 
oxygen is an essential factor known to affect the growth mechanisms of endothelial cells. 
 
 
Figure 4.11 Effect of collagen thickness on viability and proliferation for samples 
exposed to 5 ng/ml VEGF concentration. Data shown are mean values ± sd; n=3 
 
It is possible that as the collagen thickness increases, oxygen diffusion into the collagen 
is slower relative to its consumption by the cells. Literature has shown that diffusion of 
oxygen and nutrient delivery is inadequate in tissues greater than 2 mm. [133] This is 
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endothelial cell viability and proliferation is greatest for the 2.01 mm than the 0.73 mm 
and 4.28 mm collagen thicknesses.  
 
 
Figure 4.12 Effect of collagen thickness on viability and proliferation for samples 
exposed to 50 ng/ml VEGF concentration. Data shown are mean values ± sd; n=3, 
*p<0.05 vs. 0.73 mm collagen thickness sample.  
 
 For the samples with 100 ng/ml VEGF, it was observed that the samples with the 
2.01 mm collagen thickness had a significant increase in cell viability and proliferation, 
but the samples with the 4.28 mm collagen thickness was not significant, when compared 

















































collagen thickness had on average fourteen times higher viability than the samples with 
the 4.28 mm collagen thickness, and twice as high as the samples with the 0.73 mm 
collagen thickness. These results show similar effects on cell viability and proliferation as 
shown previously.  
  
Figure 4.13 Effect of collagen thickness on viability and proliferation for the 
samples exposed to 100 ng/ml VEGF concentration. Data shown are mean values ± 
sd; n=3, *p<0.05 vs. 0.73 mm collagen thickness sample.  
 
 Another significant observation from the data was the decrease in cell viability 
and proliferation from Day 3 to 6 for each collagen thickness. For 50 ng/ml VEGF added 

















































the 0.73 mm, 2.01 mm and 4.28 mm collagen thicknesses, respectively. For 100 ng/ml 
VEGF added to the samples, a decrease from 86% to 13%, 76% to 4%, 16% to 10% was 
observed for the 0.73 mm, 2.01 mm and 4.28 mm collagen thicknesses, respectively. The 
decrease in cell viability and proliferation was due to the increase in cell growth in the 
control group on Day 6. However, changing the media on Day 6 after carrying out 
analyses increased VEGF concentration in 5 ng/ml, 50 ngml, and 100 ng/ml samples and 
as a result cells were observed to increase at a rapid rate on Days 9, 12 and 15.   
 
4.2.5 Effect of collagen thickness on endothelial cell number of sprouts and 
migration 
  The effect of collagen thickness on number of sprouts was investigated (data not 
shown). For 5 ng/ml VEGF added to samples, it was observed that sprouts were 
stimulated in one sample, the 0.73 mm collagen thickness, as was seen in figure 4.9, but 
this increase was not significant compared to the control. Also for this group, the effect of 
collagen thickness on cell migration was observed to be negligible compared to the NGF 
control group (data not shown). For the samples with 50 ng/ml of VEGF, a significant 
increase in cell sprouting and migration was observed in the 0.73 mm collagen thickness 
samples compared to the control, as seen in Figure 4.9 and 4.10, respectively. There was 
no cell migration or sprouting observed in the 2.01 mm and 4.28 mm collagen 
thicknesses compared to the control (data not shown). The effect of collagen thickness on 
sprouting and migration for the addition of 100 ng/ml VEGF to samples was also studied 
(data not shown). The results showed the same effect observed for samples with 50 ng/ml 
VEGF; only the 0.73 mm collagen thickness showed significant sprouting and migration. 
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For both 50 ng/ml VEGF and 100 ng/ml VEGF added to samples, increasing collagen 
thickness from 0.73 mm to 2.01 mm stimulated higher viability and proliferation, but not 
sprouting and migration of endothelial cells. Thus, the 2.01 mm collagen thickness had 
the greatest effect on viability and proliferation, the 0.73 mm collagen thickness had the 
greatest effect on cell sprouting and migration, and the 4.28 mm collagen thickness had 
no significant effect in either of the processes.  
 For the novel 3D angiogenesis system, it was concluded that 50 ng/ml and 100 
ng/ml VEGF concentrations were more potent in stimulating viability, proliferation, 
sprouting and migration compared to the 5 ng/ml VEGF concentration. The higher VEGF 
concentrations of 50 ng/ml and 100 ng/ml exerted approximately the same effect on cell 
viability, proliferation, sprouting and migration. Taking cost into consideration, it was 
concluded that the 50 ng/ml VEGF concentration is the most suitable for this model. It 
was also concluded that 0.73 mm collagen thickness was the most suitable extracellular 
matrix environment for angiogenesis in this novel system because it showed significant 
increases in cell viability, proliferation, sprouting and migration compared to the 2.01 
mm collagen thickness, which only showed increases in cell viability and proliferation. 
These two variables, 0.73 mm collagen thickness and 50 ng/ml VEGF concentration, sets 
the platform for testing the effect of thalidomide analogue, CLT-003 on angiogenesis 











CONCLUSIONS AND RECOMMENDATIONS 
 
The main goal of this research was to develop and characterize a novel 3D 
vascular tissue model that can be used to study the effect of an anti-angiogenesis drug 
(CLT-003) on human umbilical vein endothelial cells. The motivation for this research 
was to develop an angiogenesis tissue model that mimicked human physiological 
conditions to study an anti-angiogenic drug for treating diabetic retinopathy. The newly 
developed model has great potential for commercialization. It can be used to study the 
different mechanisms associated with angiogenesis and new therapeutic strategies for 
controlling the disease.  
In vitro tissue models can serve as alternative testing models to animal or human 
models, especially in cases where either or both fail to provide the information needed.  
With animal models there is the possibility of uncertainty in results due to the differences 
in tissue response in some organs. Human models on the other hand cannot be used in 
studying anything that is considered hazardous to the human health.  The use of in vitro 
models has overcome the limitations of both animal and human models in research. There 
are two types of in vitro models; two dimensional (2D) and three dimensional (3D). The 




the third dimension essential for investigating the proliferation and migration steps of 
angiogenesis.  Without the third dimension, 2D in vitro models provide limited insight 
into the complex interactions occurring within in vivo angiogenesis. The 3D in vitro 
models are also closer to the in vivo environment than 2D models because they take into 
consideration more steps of angiogenesis process including cell migration and the 
formation of intricate capillary-like structures. Other factors such as the effect of a 
gradient of diffusion of nutrients, oxygen, and stimulating factors on the angiogenesis 
process can also be studied in 3D models.  
This project was divided into two parts. The first part was based on developing a 
3D tissue model adapted from literature to test the effect of an anti-angiogenesis drug 
(CLT-003) on endothelial cell viability, proliferation, sprouting and migration. The 
second part was based on creating a novel 3D angiogenesis tissue model that was 
characterized by studying the effect of changes in collagen thickness and VEGF 
concentration on endothelial cell viability, proliferation, sprouting and migration. The 
main conclusions from this project include: 
1) For the 3D tissue model developed using a solid plate format, the normal model 
demonstrated a more significant effect of CLT-003 on endothelial cell viability, 
proliferation and sprouting than the growth factor model. Due to the absence of a 
growth factor cocktail, the normal model was able to demonstrate the normal 
mechanism of CLT-003 in reducing angiogenesis.   
2) A novel 3D vascular tissue model that mimics angiogenesis was successfully 
developed, and the effect of changes on the design variables of collagen thickness 




3) Increasing VEGF concentration was shown to demonstrate a mitogenic effect in 
stimulating endothelial cell growth. There was no significant effect observed 
when 5 ng/ml of VEGF concentration was added to the system. An increase in 
VEGF concentration from 5 ng/ml to 50 ng/ml showed a significant increase in 
viability, proliferation, sprouting and migration of endothelial cells. However, an 
increase in VEGF concentration from 50 ng/ml to 100 ng/ml did not have a 
significant effect, showing a limit to this mitogenic effect. 
4) Varying collagen thickness had an effect on endothelial cell viability, sprouting 
and migration. Viability and proliferation increased in samples with increasing 
collagen thickness, from 0.73 mm to 2.01 mm. There was no significant increase 
in endothelial cell viability and proliferation in samples with 4.28 mm collagen 
thickness. Endothelial cell sprouting and migration were induced only in the 
tissue model with 0.73 mm collagen thickness. 
5) For the novel system, the optimal conditions that could be used to test the effect 
of anti-angiogenesis drugs on angiogenesis in the tissue model are 0.73 mm 
collagen thickness and 50 ng/ml VEGF concentration. The 0.73 mm collagen 
thickness had significant effects on all the angiogenic events analyzed in this 
model. For the VEGF concentration, since the two concentrations have 
approximately the same effect on angiogenesis within the tissue model, it is more 
economical to select the 50 ng/ml than the 100 ng/ml.  
 
A 3D model to mimic angiogenesis that occurs in vivo was initially used to study 




human umbilical vein endothelial cells (HUVECs) grown on bovine type 1 collagen 
matrix in a solid plate system. Two drug concentration were used, 32 µM and 64 µM, to 
study the potent effect of the anti-angiogenesis drug. The first model was called the 
Growth Factor Model because it used a growth factor cocktail to stimulate angiogenesis.  
It was observed that CLT-003 had a greater effect on viability, proliferation, number of 
sprouts and migration of endothelial at the higher CLT-003 concentration than the lower 
concentration. However, after the drug was added to the cells, the growth factor cocktail 
stimulated cell recovery, leading to a system that did not illustrate the normal mechanism 
of the drug. The drawbacks associated with this model led to the development of the 
second model, called the Normal Model. This model had the same design as the Growth 
Factor Model but there was no stimulant used to induce viability, proliferation and 
differentiation of endothelial cells. CLT-003 was shown to significantly affect endothelial 
cell viability, proliferation and sprouting, which made it more suitable for testing the drug 
than the Growth Factor Model. However, problems associated with this design included, 
a significant decrease in endothelial cell viability of the control samples for the duration 
of the experiment and there was no provision for drug delivery to mimic in vivo 
conditions. Therefore, a more physiological model was developed, and the effect of 
certain design parameters on angiogenesis tested. 
The novel 3D vascular tissue model consisted of HUVECs cultured on bovine 
type 1 collagen in Transwell® membrane supports. Since this was a new model and was 
significantly different from previous models, the model had to be characterized before it 
could be used to test the anti-angiogenesis drug. The effect of two design variables, 




major protein in the extracellular matrix. Three collagen thicknesses (0.73 mm, 2.01 mm 
and 4.28 mm) were chosen in order to represent different thicknesses of the extracellular 
matrix. VEGF plays a key role in pathological and physiological angiogenesis. Three 
VEGF concentrations (5 ng/ml, 50 ng/ml, 100 ng/ml) were chosen in order to study its 
mitogenic effect on endothelial cell viability, proliferation, sprouting and migration.  
For studying the effect of collagen thickness in the tissue model, viability and 
proliferation of endothelial cells increased twice as much for the samples with 2.01 mm 
collagen thickness compared to the samples with 0.73 mm collagen thickness. This 
demonstrates that extracellular matrix plays an important role in regulating endothelial 
cell behavior. It employs a direct control over the activity of growth factors through 
binding and release of certain growth factors. Through this, the extracellular matrix 
serves as a sequestration and storage site for growth factors, concentrating their activity 
in the vicinity of cells and protecting them from degradation [134]. The 2.01 mm 
collagen thickness accommodated more VEGF in the collagen and induced greater 
stimulation of viability and proliferation than the 0.73 mm collagen thickness. Cell 
viability and proliferation decreased when increasing the collagen thickness further to 
4.28 mm compared to the 0.73 mm collagen thickness.  The decrease in cell viability and 
proliferation for the 4.28 mm collagen thickness can be due to other factors, i.e.  the 
supply of oxygen, that also contribute to endothelial cell viability and proliferation [133]. 
Endothelial cell migration and the number of sprouts increased for samples with 0.73 mm 
collagen thickness compared to 2.01 mm and 4.28 mm collagen thicknesses. With 




collagen thickness, because it showed a significant effect on all four angiogenic steps: 
viability, proliferation sprouting, and migration.  
For the effect of VEGF concentration on viability, proliferation, sprouting, and 
migration, a slight increase was observed when 5 ng/ml VEGF was added to the samples, 
compared to the NGF control sample. When the VEGF concentration was increased to 50 
ng/ml, this showed a further increase in endothelial cell viability, proliferation, sprouting, 
and migration, compared to the NGF control sample. The 100 ng/ml VEGF concentration 
also showed a significant increase in the viability, proliferation, sprouting, and migration 
of endothelial cells, compared to the NGF control sample. The function of VEGF as an 
endothelial cell specific mitogen was to stimulate survival, proliferation and 
differentiation of endothelial cells. With reference to this 3D model, this effect was 
displayed in a dose-dependent manner. However, it was found that the 100 ng/ml VEGF 
concentration did not show a significant increase in viability and proliferation compared 
to the 50 ng/ml VEGF concentration. There may be a point between these two 
concentrations, which the receptors on endothelial cells become saturated with VEGF and 
there is no further mitogenic effect. With reference to this 3D vascular tissue model and 
taking cost into consideration, the 50 ng/ml VEGF concentration was chosen as the most 
suitable for endothelial cell stimulation within this model.  
The current 3D tissue model was successful in demonstrating the basic angiogenic 
steps: viability, proliferation, sprouting, and migration. However, this model needs to be 
improved upon and further characterized so that it can be used as a testing system for the 




diabetic retinopathy. Consequently, future work will be directed towards addressing the 
following: 
1) During angiogenesis, blood vessels supply both oxygen and nutrients that 
increase stimulation of endothelial cell survival. Oxygen is therefore 
important in angiogenesis [135-137] and may be a factor that affects 
endothelial cell growth when varying collagen thickness. Therefore, the effect 
of saturated oxygen concentration within the tissue model on angiogenesis 
needs to be characterized.  
2) The ECM has a high affinity for many soluble factors, including VEGF. 
Review of literature shows that angiogenic molecules may be entrapped in the 
ECM, but they are directly recognized by integrins [138, 139]. Integrins are 
receptors that mediate between a cell and the surrounding tissue. The 
interactions of VEGF binding to the ECM through integrins needs to be 
studied in order to completely characterize the effect of VEGF transport and 
interaction within the model. This could also reveal why the cell viability and 
proliferation is greater in samples with 2.01 mm collagen thickness compared 
to samples with 0.73 mm collagen thickness. 
3) Use the new model to test the anti-angiogenic properties of CLT-003 on the 
mechanisms associated with angiogenesis. This includes studying the effect of 
the route of delivery of the drug on angiogenesis in the tissue model. The 
already characterized response to CLT-003 can be used to validate the new 
model, so that it can be used for the design and testing of new therapeutics for 
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Scope and Method of Study:  
Diabetic Retinopathy (DR) is a microvascular complication associated with diabetes 
mellitus and is the leading cause of blindness in American adults.  DR occurs as a result 
of chronic hyperglycemia, which causes vascular damage, increased vascular 
permeability, vascular leakage, and edema.  When the blood glucose level is elevated in 
the body, it can lead to a production of growth factors.  Among the many growth factors 
present, vascular endothelial growth factor (VEGF) has been recognized as the primary 
mediator of vascular alteration in DR. Currently there is no non-invasive and effective 
drug treatment to prevent or arrest the progression of DR. Studies have shown that agents 
that block VEGF activity can prevent diabetes-induced retinal damage, thus the 
development of new drugs to block retinal vascular leakage via targeting VEGF or its 
receptor has become a potential new therapy for DR. Recently a novel anti-angiogenesis 
drug, a thalidomide analog, has been developed for the treatment of diabetic retinopathy. 
The objective of this research was to develop a three dimensional (3D) in vitro model to 
study the effect of an anti-angiogenesis drug on endothelial cell functions associated with 
angiogenesis. Initially, a model consisting of endothelial cells grown on bovine type 1 
collagen gel formed within a 96 solid well plate was tested. Due to drawbacks associated 
with the model, a novel 3D model was created using Transwell® permeable supports.  
The new model was characterized by varying collagen thickness at 0.73 mm, 2.01 mm 
and 4.28 mm and VEGF concentration at 5 ng/ml, 50 ng/ml, and 100 ng/ml. 
 
Findings and Conclusions:   
The higher VEGF concentrations of 50 ng/ml and 100 ng/ml showed greater stimulation 
of cell viability, proliferation, number of sprouts and migration than the 5 ng/ml 
concentration. However there was no significant increase in the endothelial cell functions 
for the 100 ng/ml of VEGF compared to the 50 ng/ml of VEGF. The 2.01 mm collagen 
thickness showed the greatest increase in cell viability and proliferation compared to the 
0.73 mm and 4.28 mm thicknesses.  The 0.73 mm collagen thickness showed the greatest 
increase in sprouting and migration compared to the 2.01 mm and 4.28 mm thicknesses. 
It can be concluded that the 0.73 mm collagen thickness and the 50 ng/ml VEGF 
concentration result in the optimal conditions suitable for testing the anti-angiogenesis 
drug in the new model.  The 0.73 mm thickness was chosen as the most suitable collagen 
thickness, because it showed a significant effect on all four angiogenic steps: viability, 
proliferation sprouting, and migration. 
